Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overcoming bcl-2- and p53-mediated resistance in prostate cancer.

Seminars in oncology - 1 Feb 1999

DiPaola R S, Aisner J

Abstract excerpt

Most prostate cancers eventually develop resistance to hormonal therapy and chemotherapies. Many mechanisms for resistance to chemotherapy have been identified. Mutations or inactivation of the p53 suppressor gene and overexpression of bcl-2 are among such mechanisms. Mutations in the p53 gene can lead to resistance to certain chemotherapy agents, and such mutations are seen more often in metastatic than in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Clinical Trials as Topic
Share to Genes, bcl-2

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genes, p53

Share to Interferons

Share to Paclitaxel

Share to Prostatic Neoplasms

Share to Tretinoin

Source

Identifiers

PMID: 10190792

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overcoming bcl-2- and p53-mediated resistance in prostate cancer.PMID 10190792Read ↗

Chemosensitization of Prostate Cancer by Modulating Bcl-2 Family ProteinsSemantic proximity Read ↗

Therapeutic Targeting of MDR1 Expression by RORγ Antagonists Resensitizes Cross-Resistant CRPC to Taxane via Coordinated Induction of Cell Death ProgramsSemantic proximity Read ↗

Bcl-2 Expression as a Predictive Marker of Hormone-Refractory Prostate Cancer Treated with Taxane-Based ChemotherapySemantic proximity Read ↗

Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells.Semantic proximity Read ↗

Selection for Drug Resistance Results in Resistance to Fas-Mediated ApoptosisSemantic proximity Read ↗

Dichloroacetate (DCA) sensitizes both wild‐type and over expressing Bcl‐2 prostate cancer cells in vitro to radiationSemantic proximity Read ↗

The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells.Semantic proximity Read ↗

Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity.Semantic proximity Read ↗

Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancerSemantic proximity Read ↗

bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cellsSemantic proximity Read ↗

P53, MDM-2, BAX and BCL-2 and Drug Resistance in Chronic Lymphocytic LeukemiaSemantic proximity Read ↗

Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.